{
  "id": "fda_guidance_chunk_0113",
  "title": "Introduction - Part 113",
  "text": "IND to allow FDA to assess the risks of the proposed change and until the change has been approved by the IRB.45 44 See 21 CFR 56.104(c) (permitting IRB exemption for emergency use of a test article). 45 See 21 CFR 312.30(b)(2)(i)(b) (permitting a protocol change to be made once the sponsor has submitted the change to FDA and the change has been approved by the IRB). 18 Contains Nonbinding Recommendations REFERENCES Abrams J, B Conley, M Mooney, J Zwiebel, A Chen, JJ Welch, N Takebe, S Malik, L McShane, E Korn, M Williams, L Staudt, and J Doroshow, 2014, National Cancer Institute’s Precision Medicine Initiatives for the New National Clinical Trials Network, Am Soc Clin Oncol Educ Book, 34:71–76. Herbst RS, DR Gandara, FR Hirsch, MW Redman, M LeBlanc, PC Mack, LH Schwartz, E Vokes, SS Ramalingam, JD Bradley, D Sparks, Y Zhou, C Miwa, VA Miller, R Yelensky, Y Li, JD Allen, EV Sigal, D Wholley, CC Sigman, GM Blumenthal, S Malik, GJ Kelloff, JS Abrams, CD Blanke, and VA Papadimitrakopoulou, 2015, Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400, Clin Cancer Res, 21(7):1514–1524. Hyman DM, I Puzanov, V Subbiah, JE Faris, I Chau, J-Y Blay, J Wolf, NS Raje, EL Diamond, A Hollebecque, R Gervais, ME Elez-Fernandez, A Italiano, R-D Hofheinz, M Hildago, E Chan, M Schuler, SF Lasserre, M Makrutzki, F Sirzen, ML Veronese, J Tabernero, and J Baselga, 2015, Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations, N Engl J Med, 373(8):726–736. Kim ES, RS Herbst, II Wistuba, JJ Lee, GR Blumenschein Jr., A Tsao, DJ Stewart, ME Hicks, J Erasmus Jr., S Gupta, CM Alden, S Liu, X Tang, FR Khuri, HT Tran, BE Johnson, JV Heymach, L Mao, F Fossella, MS Kies, V Papadimitrakopoulou, SE Davis, SM Lippman, and WK Hong, 2011, The BATTLE Trial: Personalizing Therapy for Lung Cancer, Cancer Discov, 1(1): 44–53. Simon R, 1989, Optimal Two-Stage Designs for Phase II Clinical Trials, Control Clin Trials, 10(1):1–10. Woodcock, J and LM LaVange, 2017, Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both, N Engl J Med, 377(1):62–70. 19 Contains Nonbinding Recommendations APPENDIX Example of a Master Protocol With a Basket Trial Design An example of a master protocol with basket design is the",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 150528,
  "end_pos": 152064,
  "tokens": 512,
  "tags": [
    "design",
    "regulatory",
    "clinical_trial",
    "consent"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "guidance",
  "created_at": "2025-10-23T02:25:44.684Z"
}